Drugs / paritaprevir
paritaprevir
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Viekirax | — | 2024-09-25 | europa.eu ↗ |
| Approved | EU (EMA) | Viekirax | — | 2015-01-14 | europa.eu ↗ |
| Approved | US (FDA) | VIEKIRA PAK (COPACKAGED) | — | 2014-12-19 | fda.gov ↗ |
Trials 56 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03341988 | Nov 2017 → Jan 2018 | chronic hepatitis C virus infection | Assiut University | Completed | No outcome recorded |
| Phase 1 | NCT02534870 | Sep 2015 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT02052362 | Jan → Feb 2014 | — | AbbVie | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04378608 | Jan → Sep 2017 | chronic hepatitis C virus infection | Beni-Suef University | Completed | No outcome recorded |
| Phase 214 trials | ||||||
| Phase 2 | NCT03067883 | Nov 2016 → Jan 2018 | chronic hepatitis C virus infection | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT02194998 | Sep 2015 → May 2018 | HIV infectious disease, chronic hepatitis C virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT02356562 | Feb 2015 → Oct 2016 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT02292719 | Dec 2014 → Jul 2017 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01911845 | Apr → Dec 2013 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01782495 | Feb 2013 → Nov 2016 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01609933 | Dec 2012 → May 2017 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01685203 | Aug 2012 → Jun 2014 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01672983 | Jul 2012 → May 2014 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01464827 | Oct 2011 → Mar 2013 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01458535 | Sep 2011 → May 2013 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01306617 | Feb → Nov 2011 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01221298 | Oct 2010 → May 2011 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01074008 | Mar 2010 → Jun 2011 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02486406 | Oct 2015 → Nov 2020 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2/3 | NCT02555943 | Feb 2015 → May 2021 | chronic hepatitis C virus infection, hepatitis B virus infection | Humanity and Health Research Centre | Completed | No outcome recorded |
| Phase 328 trials | ||||||
| Phase 3 | NCT02806362 | Sep 2016 → Jun 2018 | chronic hepatitis C virus infection | AbbVie | Withdrawn | No outcome recorded |
| Phase 3 | NCT02634008 | Jun 2016 → Apr 2021 | acute hepatitis C virus infection | Kirby Institute | Completed | No outcome recorded |
| Phase 3 | NCT02646111 | Jan 2016 → Jan 2018 | chronic hepatitis C virus infection | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT02582632 | Nov 2015 → Aug 2016 | hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02609659 | Oct 2015 → Oct 2016 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02487199 | Sep 2015 → Dec 2016 | hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02517528 | Jul 2015 → Sep 2016 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02517515 | Jul 2015 → Oct 2016 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02504099 | Jul 2015 → Sep 2016 | chronic hepatitis C virus infection | AbbVie | Terminated | No outcome recorded |
| Phase 3 | NCT02476617 | Jun 2015 → Aug 2016 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02442284 | May 2015 → Aug 2016 | chronic hepatitis C virus infection, cirrhosis of liver | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02442271 | Apr 2015 → Jul 2016 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02399345 | Mar → Nov 2015 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02219477 | Nov 2014 → Jun 2016 | chronic hepatitis C virus infection, cirrhosis of liver | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02219490 | Oct 2014 → May 2021 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02265237 | Oct 2014 → Jul 2016 | hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02207088 | Sep 2014 → Dec 2016 | chronic hepatitis C virus infection, cirrhosis of liver, end stage renal failure | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02216422 | Sep 2014 → Dec 2015 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02167945 | Jun 2014 → May 2021 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02023099 | Dec 2013 → Oct 2014 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01854528 | Jun 2013 → Nov 2014 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01854697 | Mar 2013 → Nov 2014 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01833533 | Mar → Dec 2013 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01767116 | Dec 2012 → Dec 2013 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01715415 | Nov 2012 → Nov 2013 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01716585 | Nov 2012 → Oct 2013 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01704755 | Oct 2012 → Jan 2014 | chronic hepatitis C virus infection, cirrhosis of liver | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01674725 | Aug 2012 → Jan 2014 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT03499639 | May → Aug 2018 | end stage renal failure, hepatitis C virus infection | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT03003338 | Oct 2017 → Oct 2018 | chronic hepatitis C virus infection | Hannover Medical School | Terminated | No outcome recorded |
| Phase 4 | NCT03050905 | Jun → Nov 2017 | hepatitis C virus infection | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| Phase 4 | NCT02874066 | Mar 2017 → Oct 2018 | viral hepatitis | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02950870 | Dec 2016 → Dec 2017 | chronic hepatitis C virus infection | University of Modena and Reggio Emilia | Unknown | No outcome recorded |
| Phase 4 | NCT02498015 | Aug 2016 → Aug 2017 | chronic hepatitis C virus infection | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT03710252 | Mar 2016 → Sep 2017 | chronic hepatitis C virus infection | American Research Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02460133 | Jul 2015 → Oct 2025 overdue | hepatitis C virus infection | Nova Scotia Health Authority | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 15 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01091649 Comparator | Feb → Apr 2010 | — | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00931281 Comparator | Jun → Sep 2009 | hepatitis C virus infection | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00909311 Comparator | May → Jul 2009 | hepatitis C virus infection | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00850044 Comparator | Feb → Jul 2009 | hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04391985 Comparator | Mar → Oct 2017 | chronic hepatitis C virus infection | Beni-Suef University | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02493855 Background | Jun 2015 → Apr 2016 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01995071 Background | Nov 2013 → Jun 2015 | chronic hepatitis C virus infection, cirrhosis of liver | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01563536 Background | Feb → Apr 2012 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02247401 Comparator | Nov 2014 → Aug 2016 | hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01773070 Background | Jun 2013 → Oct 2016 | hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT03296930 Comparator | Oct 2017 → Sep 2018 | poisoning | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT02786537 Comparator | Jun 2016 → Jun 2019 | chronic hepatitis C virus infection | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT02461745 Comparator | Jun 2015 → May 2017 | chronic hepatitis C virus infection | Kaiser Permanente | Completed | No outcome recorded |
| Phase 4 | NCT02992457 Comparator | Jan 2015 → Dec 2018 | hepatitis C virus infection | Tanta University | Completed | No outcome recorded |
| Phase 4 | NCT03133065 Comparator | Sep 2014 → Dec 2016 | — | Ain Shams University | Completed | No outcome recorded |
Press releases naming this drug 20 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-02-27 | AbbVie | AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C abbvie.com ↗ |
| 2016-09-23 | AbbVie | AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C abbvie.com ↗ |
| 2016-07-25 | AbbVie | CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A) abbvie.com ↗ |
| 2016-07-25 | AbbVie | AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C abbvie.com ↗ |
| 2016-04-25 | AbbVie | AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis abbvie.com ↗ |
| 2016-04-15 | AbbVie | AbbVie Announces Real-World Data with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) from Large German Hepatitis C-Registry abbvie.com ↗ |
| 2016-04-14 | AbbVie | AbbVie Announces High SVR Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Regardless of the Presence of Resistance-Associated Variants Prior to Treatment in Genotype 1 Chronic Hepatitis C Patients abbvie.com ↗ |
| 2016-03-30 | AbbVie | AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Investigational, Pan-Genotypic Regimen at The International Liver Congress™ 2016 abbvie.com ↗ |
| 2016-02-26 | AbbVie | AbbVie Receives CHMP Positive Opinion for VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Without Ribavirin for the Treatment of Chronic Hepatitis C in Genotype 1b Patients with Compensated Cirrhosis (Child-Pugh A) in abbvie.com ↗ |
| 2016-01-07 | AbbVie | FDA Grants Priority Review to AbbVie for Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Virus Patients with Compensated Cirrhosis abbvie.com ↗ |
| 2015-12-02 | AbbVie | AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) to Treat Genotype 1 Chronic Hepatitis C Virus Infection abbvie.com ↗ |
| 2015-11-14 | AbbVie | AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis abbvie.com ↗ |
| 2015-10-01 | AbbVie | AbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) and Ongoing Clinical Development Program at The Liver Meeting® 2015 abbvie.com ↗ |
| 2015-09-28 | AbbVie | AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C abbvie.com ↗ |
| 2015-09-11 | AbbVie | Ongoing Real World Study Reports High Sustained Viral Response Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Genotype 1 Hepatitis C Patients abbvie.com ↗ |
| 2015-07-24 | AbbVie | TECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA Approval as the First and Only All-Oral, Interferon-Free Treatment for Genotype 4 Chronic Hepatitis C in the U.S. abbvie.com ↗ |
| 2015-02-23 | AbbVie | Results from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) Published Online in JAMA; Sub-analyses to be Presented at the Annual Confere abbvie.com ↗ |
| 2015-01-16 | AbbVie | European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C abbvie.com ↗ |
| 2014-12-19 | AbbVie | AbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C abbvie.com ↗ |
| 2014-11-21 | AbbVie | CHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe abbvie.com ↗ |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 75 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | paritaprevir | “GIFT-I is a phase 3 trial evaluating the efficacy and safety of a 12-week regimen of coformulated ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) for treatment of Japanese...” PMID 26147154 ↗ Aug 201545“The combination of ombitasvir (an NS5A inhibitor), paritaprevir (an NS3/4A inhibitor) coadministered with ritonavir (r), and dasabuvir (an NS5B nonnucleoside polymerase...” PMID 26596948 ↗ Nov 2015 “one recipient is treated with fixed-dose combination of ombitasvir (12.5 mg), paritaprevir (75 mg) and ritonavir (50 mg) + weight based ribavirin due to having persistent renal...” NCT03133065 ↗ “A Monocenter Randomized Double-blind Placebo-controlled Study to Investigate Neuropsychiatric Manifestations of HCV-infection During and After Treatment With...” NCT03003338 ↗ “Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.” PMID 29909549 ↗ Feb 2019 “12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir (25/150/100 mg dose) once daily and Dasabuvir 250 mg twice daily.” NCT02646111 ↗ “Ombitasvir, paritaprevir with ritonavir (OBV/PTV/r) ± ribavirin (RBV) are approved to treat HCV genotype 4 (GT4) infection.” NCT04378608 ↗ “Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients” NCT04391985 ↗ “A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection” NCT02498015 ↗ “Paritaprevir/ritonavir/ombitasvir (PTV/r/OBV, 75mg/50mg/12.5mg per tablet, Viekirax): 2 tablets per os per day” NCT02874066 ↗ “ABT-450/r/ABT-267 (paritaprevir/ritonavir/ombitasvir; 2 direct acting antiviral agent” NCT02247401 ↗ “All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax).” NCT03050905 ↗ “ABT-450 also known as paritaprevir and r is also know as ritonavir” NCT01609933 ↗ “ABT-450 also known as paritaprevir” NCT01833533 ↗ “ABT-450 also known as paritaprevir” NCT02167945 ↗ “ABT-450 also known as paritaprevir” NCT01704755 ↗ |
| Known as | ABT-450 | “ABT-450/r/ABT-267 (paritaprevir/ritonavir/ombitasvir; 2 direct acting antiviral agent” NCT02247401 ↗29“Paritaprevir (ABT-450) is inhibitor of the NS3-4A serine protease” NCT04378608 ↗ “paritaprevir also known as ABT-450” NCT02517515 ↗ |
| Known as | ABT-450 also known as paritaprevir | “ABT-450 also known as paritaprevir” NCT01674725 ↗13“ABT-450 also known as paritaprevir” NCT02219490 ↗ “ABT-450 also known as paritaprevir” NCT02216422 ↗ “ABT-450 also known as paritaprevir” NCT01685203 ↗ “ABT-450 also known as paritaprevir” NCT02023099 ↗ “ABT-450 also known as paritaprevir” NCT01672983 ↗ “ABT-450 also known as paritaprevir” NCT01715415 ↗ “ABT-450 also known as paritaprevir” NCT01716585 ↗ “ABT-450 also known as paritaprevir” NCT02219477 ↗ “ABT-450 also known as paritaprevir” NCT01995071 ↗ “ABT-450 also known as paritaprevir” NCT01854697 ↗ “ABT-450 also known as paritaprevir” NCT01773070 ↗ “ABT-450 also known as paritaprevir” NCT01767116 ↗ “ABT-450 also known as paritaprevir” NCT01854528 ↗ |
| Known as | paritaprevir (ABT-450) | “paritaprevir (ABT-450)” NCT02265237 ↗ |
| Known as | paritaprevir also known as ABT-450 | “paritaprevir also known as ABT-450” NCT02442284 ↗7“paritaprevir also known as ABT-450” NCT01782495 ↗ “paritaprevir also known as ABT-450” NCT02399345 ↗ “paritaprevir also known as ABT-450” NCT02442271 ↗ “paritaprevir also known as ABT-450” NCT02582632 ↗ “paritaprevir also known as ABT-450” NCT02609659 ↗ “paritaprevir also known as ABT-450” NCT02207088 ↗ “paritaprevir also known as ABT-450” NCT02504099 ↗ |
| Known as | Paritaprevir component of technivie | ChEMBL registry synonym — accepted as the source's own label CHEMBL3391662 ↗ |
| Known as | Paritaprevir component of viekirax | ChEMBL registry synonym — accepted as the source's own label CHEMBL3391662 ↗ |
| Known as | PTV | “GIFT-I is a phase 3 trial evaluating the efficacy and safety of a 12-week regimen of coformulated ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) for treatment of Japanese...” PMID 26147154 ↗ Aug 20156“mini-tablet formulations of ombitasvir (OBV), paritaprevir (PTV), ritonavir, and dasabuvir (DSV) with or without ribavirin for 12 weeks in children infected with chronic...” PMID 32451952 ↗ May 2020 “Ombitasvir, paritaprevir with ritonavir (OBV/PTV/r) ± ribavirin (RBV) are approved to treat HCV genotype 4 (GT4) infection.” NCT04378608 ↗ “Paritaprevir/ritonavir/ombitasvir (PTV/r/OBV, 75mg/50mg/12.5mg per tablet, Viekirax): 2 tablets per os per day” NCT02874066 ↗ “ombitasvir, paritaprevir, and ritonavir (OBV/PTV/r)” PMID 29546644 ↗ Mar 2018 “paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)” NCT02194998 ↗ “paritaprevir (PTV; 150mg)” NCT03499639 ↗ |
| Known as | Veruprevir | ChEMBL registry synonym — accepted as the source's own label CHEMBL3391662 ↗ |
| Known as | Veruprevir anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL3391662 ↗ |
| Action | Inhibit | “experimental HCV protease inhibitor” NCT00850044 ↗ |
| Modality | Small molecule | — CHEMBL3391662 ↗ |
| Route | Oral | “all-oral ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin” PMID 26321288 ↗ Aug 2015 |